Developer docs
API playgroundTry for free, no card

Search company profiles

A3P Biomedical

Full company profile

uuid000bqb2

Namestring
A3P Biomedical
Legal namestring
A3P Biomedical AB (publ)
Websiteurl
a3p.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

A3P Biomedical is a Swedish diagnostics company headquartered in Stockholm that develops and commercializes Stockholm3, a blood-based multi-biomarker test designed for the early detection of aggressive prostate cancer. The test combines protein biomarkers, a polygenic risk score, and clinical data in a proprietary algorithm — developed at Karolinska Institutet — to identify clinically significant prostate cancer while reducing unnecessary biopsies compared to standard PSA screening. The product has been validated across multiple prospective screening trials involving more than 90,000 men in Europe and is supported by inclusion in NCCN, AUA, and Swedish national clinical guidelines, as well as a UK NICE Medtech Innovation Briefing.

The company serves hospitals, urology clinics, and regional and national prostate cancer screening programs across Sweden, Norway, Finland, Switzerland, Germany, the United Kingdom, and, since July 2024, the United States. It monetizes Stockholm3 primarily through laboratory-developed test (LDT) partnerships with established diagnostic channels — Unilabs in Europe and BioAgilytix in the U.S., alongside a November 2024 partnership with labor team in Switzerland — and through direct relationships with named health systems including Stavanger University Hospital, Capio St Görans, Zürich University Hospital, Groves Medical, Martini Klinik, and Mehiläinen, as well as Swedish regional programs (Region Stockholm, Region Värmland).

A3P operates a laboratory in Uppsala, is organized with 11–50 employees, and is led by an interim CEO following the May 2024 departure of David Rosén. The company is investing in U.S. commercialization, pursuing FDA approval, executing a multi-ethnic screening trial (SEPTA) to broaden the validated population, and has hired a VP Marketing & Sales and CFO. Funding to date includes approximately SEK 510M raised across rounds, led by a SEK 400M private placement in May 2022. The business is at an early commercial stage with undisclosed revenue.

Short descriptiontext

A3P Biomedical is a Swedish diagnostics company that develops and commercializes Stockholm3, a blood-based multi-biomarker test for early detection of aggressive prostate cancer. The company serves hospitals, urology clinics, and regional screening programs across Europe and the United States through laboratory partner channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prostate cancer diagnostics, blood-based cancer test, multi-biomarker algorithm, laboratory developed test, cancer risk stratification
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Diagnostics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeOne Time License
Description

A3P Biomedical generates revenue through its proprietary Stockholm3 blood test for early detection of aggressive prostate cancer. The test is provided as a Laboratory Developed Test (LDT) through partnerships and directly to healthcare providers.

a3p.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Pricing details1 tier
1Laboratory Developed Test (LDT) pricing through healthcare providers
ModelOtherBilling cadencePay-as-you-go
Notes

Stockholm3 is available as an LDT through BioAgilytix's catalogue in the USA and through various partners in Europe. Pricing is not publicly disclosed and appears to be arranged through healthcare provider orders.

a3p.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Stockholm3
Description

A clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer, combining protein biomarkers, genetic biomarkers, and clinical information through an algorithm

a3p.com
Core offering1 text field

A3P Biomedical develops and commercializes Stockholm3, a proprietary blood-based diagnostic test for early detection and risk stratification of aggressive prostate cancer. The test combines protein biomarkers, a polygenetic risk score, and clinical variables through a proprietary multi-biomarker algorithm to predict the probability of clinically significant prostate cancer at biopsy. It is offered as a Laboratory Developed Test (LDT) through laboratory channel partners and direct hospital relationships across Europe and the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Detects 90% of aggressive prostate cancers vs 74% for PSA at ≥3 ng/ml
+5 more records
Product overview1 text field

A3P Biomedical offers a single unified product, Stockholm3, which is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. Stockholm3 runs a combination of protein biomarkers, genetic biomarkers, and clinical information through a proprietary algorithm to generate a probability score for clinically significant cancer at biopsy. The company operates primarily through laboratory partnerships (BioAgilytix in the USA, labor team in Switzerland, Unilabs in Sweden) for sample logistics and analysis, with its Uppsala, Sweden laboratory performing core analysis. A3P Biomedical also operates A3P Lab AB as a registered healthcare provider subsidiary.

Product and service1 record
1Stockholm3
CategoryCancer Diagnostics
Description

Proprietary blood-based diagnostic test that combines protein biomarkers, a polygenetic risk score, and clinical variables through a multi-biomarker algorithm to predict the probability of clinically significant (Grade Group ≥2) prostate cancer at biopsy. Used as a reflex test after elevated PSA (1.5–20 ng/ml) or as a first-line screening tool. Available as a Laboratory Developed Test (LDT) through BioAgilytix (USA), Unilabs (Sweden), labor team (Switzerland), and direct hospital relationships across Europe.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-01
Description

Strategic partnership with labor team, a Swiss laboratory based in Goldach, makes Stockholm3 available throughout Switzerland. labor team handles all logistics and wet lab analysis for Stockholm3 in Switzerland.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-09-13
Description

A3P Biomedical and BioAgilytix entered partnership to introduce Stockholm3 as a Lab Developed Test (LDT) in the US market. BioAgilytix provides CLIA-certified laboratory services from Durham, NC. Stockholm3 became commercially available in the USA through BioAgilytix in July 2024.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-16
Description

Unilabs partnership for Stockholm3 in Sweden enables healthcare providers to order Stockholm3 through Unilabs' Labportalen portal. Sampling at Unilabs laboratories or care provider facilities, with analysis by A3P Biomedical.

4Zürich University Hospital
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

First clinic in Switzerland to use Stockholm3 for prostate cancer testing in men aged 45-75. Blood samples analyzed at A3P's Uppsala lab. Men with elevated risk offered MRI examination.

a3p.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

World-renowned prostate cancer center in Hamburg, Germany independently validated Stockholm3. Validation study showed 52% reduction of unnecessary biopsies while detecting 92% of Grade Group ≥2 prostate cancers.

6Scientific Advisory Board
Strategic tierCoreTypeStrategic or Co-development Partner
Description

A3P formed Scientific Advisory Board chaired by Prof. Per-Anders Abrahamsson (former EAU Secretary General) with members including Prof. Alberto Briganti, Prof. Markus Graefen, Prof. Henrik Grönberg, and Assoc. Prof. Jochen Walz.

a3p.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Guardant Health is a liquid biopsy leader in oncology with proprietary blood-based ctDNA technology; its scale, R&D investment, and presence in urology through Shield could enable entry into prostate cancer screening, posing a long-term competitive threat.

TypeBroad incumbent
Description

Natera offers Signatera, a tumor-informed ctDNA MRD test, and has capabilities in blood-based oncology diagnostics that could be applied to prostate cancer screening, representing a broader blood-based cancer diagnostics incumbent.

TypeDirect peer
Description

MDxHealth offers SelectMDx and ConfirmMDx, urine- and tissue-based prostate cancer diagnostic tests that similarly aim to reduce unnecessary biopsies and identify aggressive prostate cancer, directly competing with Stockholm3 in the urology biomarker space.

TypeBroad incumbent
Description

Siemens Healthineers is a broad diagnostics and imaging incumbent whose ADVIA Centaur and Atellica immunoassay platforms and urology partnerships could enable entry into prostate cancer blood-based screening at scale.

TypeDirect peer
Description

OPKO Health's 4Kscore test is a blood-based kallikrein panel for prostate cancer risk assessment, directly competing with Stockholm3 as a pre-biopsy blood test for men with elevated PSA in the same customer segment.

TypeDirect peer
Description

Myriad offers Prolaris, a tissue-based genetic test for prostate cancer aggressiveness assessment, competing with Stockholm3 in risk stratification for prostate cancer patients, particularly in post-biopsy decision-making.

TypeBroad incumbent
Description

Exact Sciences is a leading cancer diagnostics company (Cologuard, Oncotype DX) with established US sales infrastructure and payor relationships that it could leverage if it entered prostate cancer screening, representing a broad incumbent threat in the oncology diagnostics space.

TypeEmerging player
Description

Epigenomics develops blood-based cancer screening tests including colorectal screening (Epi proColon), with research capabilities in DNA methylation biomarkers that could be extended toward prostate cancer applications, representing an emerging molecular diagnostics peer.

TypeOthers
Description

Bio-Techne provides protein biomarker reagents and analytical tools (including Simple Western and Ella platforms) used in biomarker assay development; comparable as an enabling tools provider in the same biomarker diagnostics ecosystem as Stockholm3.

TypeBroad incumbent
Description

Philips offers IntelliSpace Prostate, an AI-based prostate cancer detection and reporting solution integrated with MRI workflows, competing in the broader prostate cancer diagnostic pathway where Stockholm3 is positioned as a triage/reflex test.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

A3P Biomedical

Cancer Diagnosticsa3p.com

A3P Biomedical is a Swedish diagnostics company that develops and commercializes Stockholm3, a blood-based multi-biomarker test for early detection of aggressive prostate cancer. The company serves hospitals, urology clinics, and regional screening programs across Europe and the United States through laboratory partner channels.

What A3P Biomedical does

A3P Biomedical is a Swedish diagnostics company headquartered in Stockholm that develops and commercializes Stockholm3, a blood-based multi-biomarker test designed for the early detection of aggressive prostate cancer. The test combines protein biomarkers, a polygenic risk score, and clinical data in a proprietary algorithm — developed at Karolinska Institutet — to identify clinically significant prostate cancer while reducing unnecessary biopsies compared to standard PSA screening. The product has been validated across multiple prospective screening trials involving more than 90,000 men in Europe and is supported by inclusion in NCCN, AUA, and Swedish national clinical guidelines, as well as a UK NICE Medtech Innovation Briefing.

The company serves hospitals, urology clinics, and regional and national prostate cancer screening programs across Sweden, Norway, Finland, Switzerland, Germany, the United Kingdom, and, since July 2024, the United States. It monetizes Stockholm3 primarily through laboratory-developed test (LDT) partnerships with established diagnostic channels — Unilabs in Europe and BioAgilytix in the U.S., alongside a November 2024 partnership with labor team in Switzerland — and through direct relationships with named health systems including Stavanger University Hospital, Capio St Görans, Zürich University Hospital, Groves Medical, Martini Klinik, and Mehiläinen, as well as Swedish regional programs (Region Stockholm, Region Värmland).

A3P operates a laboratory in Uppsala, is organized with 11–50 employees, and is led by an interim CEO following the May 2024 departure of David Rosén. The company is investing in U.S. commercialization, pursuing FDA approval, executing a multi-ethnic screening trial (SEPTA) to broaden the validated population, and has hired a VP Marketing & Sales and CFO. Funding to date includes approximately SEK 510M raised across rounds, led by a SEK 400M private placement in May 2022. The business is at an early commercial stage with undisclosed revenue.

A3P Biomedical firmographics

Firmographics
Name
A3P Biomedical
Legal name
A3P Biomedical AB (publ)
Website
https://a3p.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
A3P Biomedical is a Swedish diagnostics company that develops and commercializes Stockholm3, a blood-based multi-biomarker test for early detection of aggressive prostate cancer. The company serves hospitals, urology clinics, and regional screening programs across Europe and the United States through laboratory partner channels.
Ownership category
akta.pro rank

A3P Biomedical industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Prostate cancer diagnostics
  • Blood-based cancer test
  • Multi-biomarker algorithm
  • Laboratory developed test
  • Cancer risk stratification

Where A3P Biomedical is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

A3P Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Diagnostic Testing Services: A3P Biomedical generates revenue through its proprietary Stockholm3 blood test for early detection of aggressive prostate cancer. The test is provided as a Laboratory Developed Test (LDT) through partnerships and directly to healthcare providers.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLaboratory Developed Test (LDT) pricing through healthcare providers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

A3P Biomedical product offering

Product offering

Core offering

A3P Biomedical develops and commercializes Stockholm3, a proprietary blood-based diagnostic test for early detection and risk stratification of aggressive prostate cancer. The test combines protein biomarkers, a polygenetic risk score, and clinical variables through a proprietary multi-biomarker algorithm to predict the probability of clinically significant prostate cancer at biopsy. It is offered as a Laboratory Developed Test (LDT) through laboratory channel partners and direct hospital relationships across Europe and the United States.

Product overview

A3P Biomedical offers a single unified product, Stockholm3, which is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. Stockholm3 runs a combination of protein biomarkers, genetic biomarkers, and clinical information through a proprietary algorithm to generate a probability score for clinically significant cancer at biopsy. The company operates primarily through laboratory partnerships (BioAgilytix in the USA, labor team in Switzerland, Unilabs in Sweden) for sample logistics and analysis, with its Uppsala, Sweden laboratory performing core analysis. A3P Biomedical also operates A3P Lab AB as a registered healthcare provider subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • Stockholm3: A clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer, combining protein biomarkers, genetic biomarkers, and clinical information through an algorithm

Products and services

  • Stockholm3 Proprietary blood-based diagnostic test that combines protein biomarkers, a polygenetic risk score, and clinical variables through a multi-biomarker algorithm to predict the probability of clinically significant (Grade Group ≥2) prostate cancer at biopsy. Used as a reflex test after elevated PSA (1.5–20 ng/ml) or as a first-line screening tool. Available as a Laboratory Developed Test (LDT) through BioAgilytix (USA), Unilabs (Sweden), labor team (Switzerland), and direct hospital relationships across Europe.

Quantifiable outcome

  • Detects 90% of aggressive prostate cancers vs 74% for PSA at ≥3 ng/ml
  • +5 more outcomes

Companies that use A3P Biomedical

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

A3P Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

A3P Biomedical partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • labor teamcoreChannel Partner/ Reseller/ Distributor · 1 November 2024Strategic partnership with labor team, a Swiss laboratory based in Goldach, makes Stockholm3 available throughout Switzerland. labor team handles all logistics and wet lab analysis for Stockholm3 in Switzerland.
  • BioAgilytixcoreChannel Partner/ Reseller/ Distributor · 13 September 2023A3P Biomedical and BioAgilytix entered partnership to introduce Stockholm3 as a Lab Developed Test (LDT) in the US market. BioAgilytix provides CLIA-certified laboratory services from Durham, NC. Stockholm3 became commercially available in the USA through BioAgilytix in July 2024.
  • UnilabscoreChannel Partner/ Reseller/ Distributor · 16 June 2022Unilabs partnership for Stockholm3 in Sweden enables healthcare providers to order Stockholm3 through Unilabs' Labportalen portal. Sampling at Unilabs laboratories or care provider facilities, with analysis by A3P Biomedical.
  • Zürich University HospitalcoreImplementation/ SI/ Consulting PartnerFirst clinic in Switzerland to use Stockholm3 for prostate cancer testing in men aged 45-75. Blood samples analyzed at A3P's Uppsala lab. Men with elevated risk offered MRI examination.
  • Martini KlinikcoreStrategic or Co-development PartnerWorld-renowned prostate cancer center in Hamburg, Germany independently validated Stockholm3. Validation study showed 52% reduction of unnecessary biopsies while detecting 92% of Grade Group ≥2 prostate cancers.
  • Scientific Advisory BoardcoreStrategic or Co-development PartnerA3P formed Scientific Advisory Board chaired by Prof. Per-Anders Abrahamsson (former EAU Secretary General) with members including Prof. Alberto Briganti, Prof. Markus Graefen, Prof. Henrik Grönberg, and Assoc. Prof. Jochen Walz.

Scale indicators8 records

Recent moves12 records

Expansion highlights6 records

A3P Biomedical competitors and assessment

Company assessment

Broad incumbents

  • Guardant Health: Guardant Health is a liquid biopsy leader in oncology with proprietary blood-based ctDNA technology; its scale, R&D investment, and presence in urology through Shield could enable entry into prostate cancer screening, posing a long-term competitive threat.
  • Natera: Natera offers Signatera, a tumor-informed ctDNA MRD test, and has capabilities in blood-based oncology diagnostics that could be applied to prostate cancer screening, representing a broader blood-based cancer diagnostics incumbent.
  • Siemens Healthineers: Siemens Healthineers is a broad diagnostics and imaging incumbent whose ADVIA Centaur and Atellica immunoassay platforms and urology partnerships could enable entry into prostate cancer blood-based screening at scale.
  • Exact Sciences: Exact Sciences is a leading cancer diagnostics company (Cologuard, Oncotype DX) with established US sales infrastructure and payor relationships that it could leverage if it entered prostate cancer screening, representing a broad incumbent threat in the oncology diagnostics space.
  • Philips (IntelliSpace Prostate): Philips offers IntelliSpace Prostate, an AI-based prostate cancer detection and reporting solution integrated with MRI workflows, competing in the broader prostate cancer diagnostic pathway where Stockholm3 is positioned as a triage/reflex test.

Direct peers

  • MDxHealth: MDxHealth offers SelectMDx and ConfirmMDx, urine- and tissue-based prostate cancer diagnostic tests that similarly aim to reduce unnecessary biopsies and identify aggressive prostate cancer, directly competing with Stockholm3 in the urology biomarker space.
  • OPKO Health (4Kscore): OPKO Health's 4Kscore test is a blood-based kallikrein panel for prostate cancer risk assessment, directly competing with Stockholm3 as a pre-biopsy blood test for men with elevated PSA in the same customer segment.
  • Myriad Genetics: Myriad offers Prolaris, a tissue-based genetic test for prostate cancer aggressiveness assessment, competing with Stockholm3 in risk stratification for prostate cancer patients, particularly in post-biopsy decision-making.

Emerging players

  • Epigenomics: Epigenomics develops blood-based cancer screening tests including colorectal screening (Epi proColon), with research capabilities in DNA methylation biomarkers that could be extended toward prostate cancer applications, representing an emerging molecular diagnostics peer.

Others

  • Bio-Techne: Bio-Techne provides protein biomarker reagents and analytical tools (including Simple Western and Ella platforms) used in biomarker assay development; comparable as an enabling tools provider in the same biomarker diagnostics ecosystem as Stockholm3.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

A3P Biomedical social profiles

Digital presence

A3P Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

A3P Biomedical leadership team

Management profile

Number of profiles

Profiles7 records

A3P Biomedical subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

A3P Biomedical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

A3P Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A3P Biomedical

What does A3P Biomedical do?

A3P Biomedical develops and commercializes Stockholm3, a proprietary blood-based diagnostic test for early detection and risk stratification of aggressive prostate cancer. The test combines protein biomarkers, a polygenetic risk score, and clinical variables through a proprietary multi-biomarker algorithm to predict the probability of clinically significant prostate cancer at biopsy. It is offered as a Laboratory Developed Test (LDT) through laboratory channel partners and direct hospital relationships across Europe and the United States.

Is A3P Biomedical a public or private company?

A3P Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was A3P Biomedical founded?

A3P Biomedical was founded in 2020. It employs 11 to 50 people.

Where is A3P Biomedical based?

A3P Biomedical is headquartered in Stockholm, Sweden, in the Europe region.

How does A3P Biomedical make money?

One revenue line is on record: diagnostic Testing Services.

Who are A3P Biomedical's main competitors?

Broad incumbents on record are Guardant Health, Natera, Siemens Healthineers, Exact Sciences and Philips (IntelliSpace Prostate). Direct peers are MDxHealth, OPKO Health (4Kscore) and Myriad Genetics. Epigenomics is listed as an emerging player. Bio-Techne is listed as an others.

Does A3P Biomedical have an API?

No public API is recorded for A3P Biomedical.

What industry is A3P Biomedical in?

A3P Biomedical's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewA3P Biomedical AB (publ) Appoints North America PresidentA3P Biomedical AB appointed Matt Franklin as President of North America, joining the Executive Management Team and reporting to CEO Martin Steinberg. The appointment supports US market access for Stockholm3, with no financial impact disclosed.Fox NewsNew blood test detects 90% of aggressive prostate cancer cases, beating current screeningsResearchers from the Karolinska Institutet in Sweden published a study in the Annals of Internal Medicine showing that the Stockholm3 blood test detected 90% of aggressive prostate cancer cases in over 12,000 men aged 50-74, compared to 74% for the standard PSA test. The test, developed by A3P Biomedical, could enable earlier detection of aggressive disease while reducing unnecessary follow-up procedures. The company plans to seek FDA approval to use the test for routine screening in the United States.BioSpacePioneering screening test offers potential to find more aggressive prostate cancersA study of 12,670 men published in Annals of Internal Medicine found Stockholm3 had 90% sensitivity and 89% specificity for aggressive prostate cancer, outperforming PSA thresholds. PSA ≥3 ng/ml had 74% sensitivity, while PSA ≥4 ng/ml had only 52% sensitivity, missing nearly half of cases.FinancialContent Business PagePioneering screening test offers potential to find more aggressive prostate cancersA3P Biomedical announced publication of a population-based screening study in Annals of Internal Medicine showing its Stockholm3 test detected 90% of aggressive prostate cancers (Grade Group ≥2) compared to 74% for standard PSA testing at ≥3 ng/ml. The study of 12,670 men aged 50–74 found Stockholm3 correctly identified 400 out of 443 men with cancer while maintaining a similar false-positive rate to PSA testing (11% vs 10%). The company stated it believes this evidence supports establishing Stockholm3 as a first-line screening test for prostate cancer.GlobeNewswirePioneering screening test offers potential to find more aggressive prostate cancersA3P Biomedical announced publication of a population-based screening study in Annals of Internal Medicine, showing their Stockholm3 test achieved 90% sensitivity and 89% specificity for detecting aggressive prostate cancer in 12,670 men aged 50–74, significantly outperforming standard PSA tests which showed 74% sensitivity at ≥3 ng/ml and only 52% sensitivity at ≥4 ng/ml. The study found Stockholm3 identified 400 out of 443 men with cancer compared to 327 and 231 respectively for PSA thresholds, while maintaining similar false-positive rates. The company stated this growing clinical evidence of over 90,000 men evaluated positions Stockholm3 as a potential first-line screening test, though it remains an investigational device not yet available for sale in the United States.StenasessanA3P Biomedical – Stena SessanA3P Biomedical focuses on advanced prostate cancer diagnostics through its Stockholm3 test, which aims to improve diagnostic precision for patients. The test utilizes a combination of protein markers, genetic markers, clinical data, and a proprietary algorithm and has been validated in studies involving over 75,000 men. This innovation seeks to significantly enhance the quality of life for men facing prostate cancer.PR NewswireA3P Biomedical AB: Fast track publication of the STHLM3 MRI trial in The Lancet OncologyA3P Biomedical AB announced that its STHLM3 MRI clinical trial involving 12,750 men has been fast-tracked for publication in The Lancet Oncology, a prestigious peer-reviewed journal. The trial demonstrated that combining the company's Stockholm3 blood test with MRI reduces unnecessary biopsies by 74% and MRI procedures by 36% compared to standard PSA testing, while maintaining detection of significant prostate cancer. The company is now pursuing global availability of the Stockholm3 test, which has already been adopted by leading Nordic healthcare providers.